• This record comes from PubMed

Prognostické faktory karcinomu děložního hrdla
[Prognostic factors for cervical cancer]

. 2013 ; 26 (2) : 83-90.

Language Czech Country Czech Republic Media print

Document type English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review

Links

PubMed 23718666
DOI 10.14735/amko201383
PII: 40616

Standardized gynecological oncological therapeutical guidelines are based on ordinary predictive factors, such as depth of stromal invasion, histopathological type of tumor, lymphovascular space invasion, lymph node metastases. Unfortunately, the power of these prognostic factors is not able to determine the safety of this procedure in the relation to disease recurrence in a group of patients who are indicated for conservative operations. This is the appropriate area for new, especially biomolecular prognostic factors (proteins: p63, TAp63, p16, p21, p27, COX-2, genes: hTERC, MYCC). Moreover, comprehensive evaluation of cervical cancer prognostic factors and assessment of new biomarkers of cancer can ease prediction of risk of spread outside primary localization and determine probability of disease recurrence. This information can help to individualize surgical, radiotherapeutic and chemotherapeutic treatment.

References provided by Crossref.org

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...